Gene Dosage Effects of the Imprinted Delta-Like Homologue 1 (Dlk1/Pref1) in Development: Implications for the Evolution of Imprinting by da Rocha, ST et al.
Gene dosage effects of the imprinted delta-like homologue 1 (dlk1/pref1)
in development: implications for the evolution of imprinting.
da Rocha, ST; Charalambous, M; Lin, SP; Gutteridge, I; Ito, Y; Gray, D; Dean, W; Ferguson-
Smith, AC
 
 
 
 
 
© 2009 Teixeira da Rocha et al.
CC-BY
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12256
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
Gene Dosage Effects of the Imprinted Delta-Like
Homologue 1 (Dlk1/Pref1) in Development: Implications
for the Evolution of Imprinting
Simao Teixeira da Rocha1, Marika Charalambous1, Shau-Ping Lin2, Isabel Gutteridge1, Yoko Ito1, Dionne
Gray1, Wendy Dean3, Anne C. Ferguson-Smith1*
1Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom, 2 Institute of Biotechnology, College of Bioresources
and Agriculture, National Taiwan University, Taipei, Taiwan, 3Developmental Genetics and Imprinting Laboratory, The Babraham Institute, Cambridge, United Kingdom
Abstract
Genomic imprinting is a normal process that causes genes to be expressed according to parental origin. The selective
advantage conferred by imprinting is not understood but is hypothesised to act on dosage-critical genes. Here, we report a
unique model in which the consequences of a single, double, and triple dosage of the imprinted Dlk1/Pref1, normally
repressed on the maternally inherited chromosome, can be assessed in the growing embryo. BAC-transgenic mice were
generated that over-express Dlk1 from endogenous regulators at all sites of embryonic activity. Triple dosage causes
lethality associated with major organ abnormalities. Embryos expressing a double dose of Dlk1, recapitulating loss of
imprinting, are growth enhanced but fail to thrive in early life, despite the early growth advantage. Thus, any benefit
conferred by increased embryonic size is offset by postnatal lethality. We propose a negative correlation between gene
dosage and survival that fixes an upper limit on growth promotion by Dlk1, and we hypothesize that trade-off between
growth and lethality might have driven imprinting at this locus.
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Introduction
Genomic imprinting, the process causing genes to be differen-
tially expressed according to their parental origin acts on a subset
of developmentally regulated genes [reviewed in 1]. Since
imprinting results in functional haploidy of target genes, the
evolution of such a mechanism must have conferred a significant
advantage to its recipients to offset the cost. In addition, the
maintenance of this method of gene dosage regulation must confer
a continuing selective benefit to the individual. By creating genetic
models that mimic the loss of imprinting of genes regulated in this
way, we can study phenotype and consider what selective pressures
act to maintain gene dosage, and begin to examine what may have
driven the acquisition of mono-allelic expression.
Dlk1, Delta-like homologue 1 also known as Preadipocyte factor 1
(Pref1), on mouse chromosome 12 is part of an imprinted gene
cluster [2,3]. It encodes a transmembrane glycoprotein that
possesses six epidermal growth factor-like motifs in the extracel-
lular domain similar to those present in the Delta/Notch/Serrate
family of signalling molecules. In contrast to other NOTCH
ligands, DLK1 does not have the Delta:Serrate:Lin-12 (DSL) domain
believed to mediate the interaction and activation of the NOTCH
receptor [4]. Nevertheless, DLK1 can interact with NOTCH
through specific EGF-like repeats and can act as a Notch antagonist,
both in culture and in vivo, binding to the receptor without
activating it [5,6,7]. In vitro, Dlk1 maintains precursor cell
populations and inhibits differentiation [4,8,9]. Dlk1 is expressed
at high levels in a wide range of embryonic tissues [10,11] however
its developmental functions in vivo are largely unknown.
In more ancestral vertebrates such as the fish Oryzias latipes and
Fugu rubripes, Dlk1, and its neighbour Dio3 which encodes a
negative regulator of thyroid hormone metabolism, are only 10–
15 Kb apart. In eutherian mammals, the genes have become
separated by the insertion of sequences including a retrotranspo-
son-like gene (Rtl1) and several non-coding RNAs, including a
large microRNA cluster, and have acquired imprinting [12]. Dlk1,
Rtl1 and Dio3 are expressed from the paternally inherited
chromosome and the non-coding RNAs from the maternally-
inherited chromosome [13].
Imprinting on chromosome 12 is controlled by an intergenic
differentially methylated region (IG-DMR) that is methylated on
the paternally inherited chromosome [14,15]. The unmethylated
maternal IG-DMR is necessary to repress protein-coding tran-
scription and to activate the non-coding RNAs [14]. In terms of
gene expression, the paternal chromosome 12 most likely
resembles the ancestral (pre-imprinted) state as Dlk1 and Dio3
are expressed and the non-coding RNAs are silenced [12].
Furthermore, paternal deletion of the methylated IG-DMR has no
effect on transcription [14].
Alteration of imprinting at chromosome 12 has considerable
consequences for embryonic fitness. Uniparental disomy mice with
two paternal copies and no maternal copy (PatDi(12)/PatDp
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(dist12)) or mice with two maternal copies and no paternal copy
(MatDi(12)/MatDp(dist12)) of chromosome 12, are lethal and
show distinct phenotypes. These include growth abnormalities and
developmental defects in muscle, cartilage/bone and placenta
[16,17,18]. Animals die prenatally commencing at E16. The
embryonic uniparental disomic phenotypes can be ascribed to the
Dlk1-Dio3 imprinted cluster because embryos with maternal
deletion of the IG-DMR (DIG-DMRMAT) recapitulate the
transcriptional profile and embryonic mutant phenotypes of the
PatDi(12)/PatDp(dist12) conceptuses [14,19].
Since loss of imprinting at chromosome 12 is lethal, there are
clear advantages in maintaining the imprinted state. However
since in PatDi(12)/PatDp(dist12) and DIG-DMRMAT conceptuses
multiple paternally expressed coding genes are up-regulated, and
multiple maternally expressed non-coding genes are repressed, we
are unable to determine if selection is acting to maintain the
mono-allelic expression of one or all protein coding genes or to
maintain expression of the non-coding RNAs. As Dlk1 is an
ancestral gene at this imprinted locus and it is expressed at high
levels in tissues where uniparental disomy conceptuses have the
most pronounced abnormalities [10], we consider Dlk1 as a strong
candidate for the pathological defects associated with the Dlk1-
Dio3 region. Therefore in this study, we specifically ask if
imprinting might be maintained to prevent overdose of Dlk1 and
moreover, if selection to control the dosage of this gene might have
driven the evolution of imprinting of the chromosome 12 cluster.
Manipulating imprinted gene dosage in vivo provides a powerful
tool to study imprinted gene function and evolution. Here we
describe a Dlk1 over-expression model in which the gene is driven
by its own endogenous regulatory sequences. We generate mouse
lines harbouring bacterial artificial chromosome (BAC) transgenes
that encompass the entire unmanipulated Dlk1 gene with different
lengths of flanking sequence. Of these, transgenic Dlk1 expression
at sites where the endogenous gene is expressed, was achieved
from a 70 kb BAC transgene in three independent lines and the
outcome was the same for all three lines. This allowed us to
compare the phenotypes of mice expressing a double (transgene
hemizygotes) or triple (transgene homozygotes) dose of Dlk1 with
normal animals expressing a single imprinted dose. This
transgenic system of regulated Dlk1 over-dose allowed us to
explore the developmental and physiological functions of this gene
in comparison with other models, and infer evolutionary scenarios
for Dlk1 imprinting.
Results
Construction of a Transgenic System for the Alteration of
Dlk1/Pref1 Dosage
BAC transgenes were generated that encompass the entire Dlk1
gene and endogenous flanking sequences but without other genes
in the cluster. Transgenic mice were created by pronuclear
injection of two BAC transgenes differing in the amounts of
flanking regulatory sequences (Figure 1A): TgDlk1-31 starts 8 kb
upstream of the Dlk1 gene and ends approximately 18 kb
downstream of the Dlk1 transcriptional start site. The TgDlk1-70
transgene shares its 39 end with the TgDlk1-31 transgene but
contains 49.4 kb of sequence upstream of Dlk1 (Figure 1A). The
four independent lines containing the TgDlk1-31 transgene failed to
express Dlk1 and no Dlk1-associated phenotypes were observed
(data not shown) regardless of transgene copy number (Figure
S1A). These mice were not analysed further. In contrast, the
TgDlk1-70 transgenic animals successfully expressed Dlk1 (Figure 1B
and C and Table S1), and were subjected to further analysis.
The four independent TgDlk1-70 lines of mice, hitherto referred
to as 70A, 70B, 70C and 70D were maintained as hemizygotes
(referred to as WT/TG) and bred to C57BL/6 for more than ten
generations to ensure stability of copy number and phenotype.
Copy number was stable from the third generation onwards and
estimated to be 4–5 (70A), 5–6 (70B), 7 (70C) and 1 (70D) (Figure
S1 and Table S1). Once stable lines were established, analysis of
the overall level of Dlk1 expression was performed by Northern
Blotting for the different lines.
In the single copy 70D line, no transgene-derived Dlk1
expression was observed and no phenotypic consequences were
noted (data not shown). This line was not analysed further.
Importantly, for the 70A, 70B and 70C lines, WT/TG E16
embryos expressed approximately twice as much Dlk1 as their
normal littermates regardless of copy number. Representative
quantitative Northern blot expression data is illustrated in
Figure 1B and 1C for 70C and 70B families. Detailed expression
data (both from Northern blots and RT-qPCR) are shown
independently for the three lines in Figure S2B and STable S1).
This expression analysis using two independent methods clearly
shows that WT/TG E16 and E18 embryos for the three lines
express approximately twice as much Dlk1.
Interestingly, expression of the transgene occurred independent
of the parental-origin of the transgene in the three independent
lines (Figure 1B; Table S1). Absence of transgene imprinting was
confirmed using a single nucleotide polymorphism (SNP) located
in the 39UTR of Dlk1 (Lin et al., 2003) allowing the endogenous
gene to be distinguished from the transgene (Figure S2A; Table
S1).
As the transgene is not imprinted, homozygous transgenic mice
(TG/TG) were generated to further increase the dosage of Dlk1 in
the three transgene expressing lines. As illustrated in Figure 1C for
70B and shown also for 70A and 70C (Figure S2 and Table S1)
levels of Dlk1 in the E16–E18 TG/TG embryos were approxi-
mately 3-fold higher than normal littermates.
Dlk1 regulation is complex involving alternative splicing and
extensive post-translational modifications, therefore we compared
DLK1 protein isoforms between the genotypes (for the 70B
family). DLK1 protein levels in the different genotypes are
consistent with the Dlk1 mRNA expression and we saw no change
in isoform preference (Figure 1D; Figure 2B). Furthermore, DLK1
protein levels in WT/TG embryos are comparable to that of
Author Summary
Genomic imprinting, the process that causes genes to be
expressed from one of the two chromosome homologues
according to parental origin, is likely to act on genes
whose dosage is important for their correct function. To
test this, we compared the phenotype of transgenic mice
expressing a double and triple dose of the imprinted gene
Dlk1/Pref1 with animals expressing the normal single dose
expressed from the paternally inherited chromosome. Our
results showed that a triple dose causes severe develop-
mental abnormalities and death before or at birth.
Embryos expressing a double dose, recapitulating absence
of imprinting, are bigger at birth but then around one-
third of them died within the first three days of life. Those
that survived had poor early growth performance in the
first week of life becoming small and remaining small, thus
offsetting any benefit conferred by being born bigger.
Therefore, imprinted levels of Dlk1/Pref1 represent the
optimal balance of growth versus lethality. These findings
lead to speculation about the evolutionary pressures
acting to establish and maintain imprinting at this locus.
Function of Dlk1 Dosage Control by Imprinting
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Figure 1. Generation of Dlk1 transgenic mice. A. Two different BAC transgenes containing the Dlk1 gene. The left panel displays a schematic
representation of the two BAC transgenes containing Dlk1 presented in this study: TgDlk1-31 and TgDlk1-70. TgDlk1-31 did not express the transgene and
was not further analysed. Red box - maternally expressed gene Gtl2; blue box – paternally expressed gene Dlk1; white circle – unmethylated IG-DMR;
black circle – methylated IG-DMR; brown line – vector sequence; Probes: violet line – Dlk1 upstream region probe, green line – Dlk1 exon 5 probe. The
right panel contains representative Southern hybridizations of the restriction enzyme fragments of the BAC 153O05 clone from where TgDlk1-31
(arrowhead) and TgDlk1-70 (arrow) were obtained by restriction digestion; the two probes were used to confirm the presence of appropriate restriction
fragments containing the Dlk1 gene and upstream sequences within the transgene. Lane 1: SgrAI; Lane 2: SgrAI+SalI; Lane 3: SnaBI; Lane 4: SnaBI+SalI;
Lane 5: PvuI; Lane 6: PvuI+SalI; Lane 7: SalI. B. Expression of Dlk1 in transgene hemizygotes is independent of parental inheritance of the transgene.
Quantitative Northern Blot showing that Dlk1 is over-expressed upon both maternal and paternal transmission of the TgDlk1-70 transgene in E16 70C
fetuses. The graph represents mean normalized Dlk1 expression6SEM (ratio: Dlk1/Gapdh) from WT/TG and WT/WT littermates upon maternal or
paternal transmission of the transgene. Significant differences between the WT/TG and WT/WT littermates are indicated by asterisks (p-value,0.05,
unpaired Student’s t test); Abbreviations: N – WT/WT fetus; T – WT/TG fetus; Mat – maternal transmission; Pat – paternal transmission. C. Double and
triple dosage of Dlk1 in hemizygous and homozygous TgDlk1-70 transgenic mice. The graph on the left represents normalized Dlk1 expression from
E16 70B WT/WT, WT/TG and TG/TG fetuses from heterozygous intercrosses obtained by Northern Blot analysis (as in B). Significant differences
between the WT/TG and WT/WT and between TG/TG and WT/WT are indicated by asterisks (p-value,0.01, unpaired Student’s t test; n$4 for all
genotypes). D. Comparative DLK1 protein levels in transgenic and PatDi(12) E16 70B fetuses and control littermates were evaluated by Western Blot
(right panel). Antibodies used were anti-DLK1 and anti a-TUBULIN (TUB) as a normalization control. Comparable protein isoforms are evident
between WT/WT and the transgenic animals on longer exposure.
doi:10.1371/journal.pgen.1000392.g001
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PatDi(12) embryos, and are further increased in TG/TG
conceptuses.
TgDlk1-70 Transgene Recapitulates the Spatio-Temporal
Expression of the Endogenous Locus in Embryonic
Tissues
Overall levels of Dlk1 expression were assessed in WT/WT and
WT/TG embryonic tissues at E16 (Table S1) and E18 by
TaqMan RT-qPCR for 70B (Figure 2A) and 70A (Table S1).
Results show that Dlk1 levels are over-expressed around 2–2.5 fold
in embryonic tissues analysed in the WT/TG when compared to
normal littermates (Figure 2A). The placenta was the only tissue
with no significant over-expression (109%6615% compared to
WT/WT) (Figure 2A and Table S1). This suggests that key
placenta specific regulators lie outside the region delineated by the
transgene.
Western Blot analysis of DLK1 protein expression was
conducted in control, WT/TG and TG/TG tissues and compared
with the RT-qPCR analysis. In all cases, using this semi-
quantitative method, protein levels correlated with RNA levels
for the tissues and stages analysed (Figure 2B). Curiously, a slight
increase in DLK1 protein levels was observed in the TG/TG
placenta, suggesting that there is minimal expression of the
transgene in this tissue.
Tissue-specific expression of Dlk1 was compared between
normal and transgenic conceptuses by in situ hybridisation and
no ectopic Dlk1 activity was evident (Figure 3 and Table S4) at
E16 or E18. This suggests that endogenous regulators are present
on the transgene and are driving transgenic Dlk1 transcription.
Tissue-specific expression of the endogenous neighbouring non-
coding RNA gene, Gtl2 was unaffected in all genotypes (data not
shown) allowing phenotypes of the transgenic mice to be attributed
to Dlk1 over-expression. Phenotypic characterization was per-
formed independently in all three lines and all the observed
phenotypes were consistent so data was combined. Results
generated from the individual lines are presented and also
summarised in the Supplementary Data.
Dlk1 Over-Dose Leads to Embryonic Growth
Enhancement Independent of the Placenta
Imprinted genes have long been known to function in
controlling pre-natal growth and nutrient acquisition [20]. To
address a growth function for Dlk1, we performed extensive
measurements of wet and dry embryonic masses, placental wet
masses and crown-rump lengths. WT/TG fetuses are expressing a
double dose of Dlk1 and showed consistent overgrowth from E16
to the day of birth. Wet and dry embryonic masses and crown-
rump (C–R) length values increased by 6–10% compared to WT/
WT littermates (Figure 4A–B; Table S3). TG/TG fetuses show
growth enhancement at E16 (wet mass and dry mass increases of
23–25%). In contrast, no differences are observed in E18 C–R
length and dry mass compared to WT/WT littermates most likely
due to the failure to thrive of these severely compromised fetuses at
the later stages as has been observed in other models [16].
Differences in wet mass between TG/TG and WT/WT at late
Figure 2. TgDlk1-70 transgene recapitulates the expression of the endogenous locus in embryonic tissues but not in the placenta. A.
Dlk1 tissue expression analysis by TaqMan RT-qPCR shown for E18. Graphic representation of relative mean Dlk1 expression in WT/WT and WT/TG
tissues normalized to 100% E18 WT/WT tongue expression6SEM (n$5). Data is shown for the 70B family. Significant differences between WT/TG and
WT/WT for each tissue at each embryonic stage are indicated by asterisks on top of the WT/TG bar (p-value,0.05; unpaired Student’s t test). Fold
differences between wild-type and transgenic conceptuses are: Br: 3.21660.37 of Dlk1 WT/WT expression; He: 2.55660.35; Lu: 1.61660.20, Li:
1.31660.21 NS; Pa: 1.65660.14; To: 1.87660.11, He: 2.99660.4, BAT: 2.41660.44; and Ki: 2.49660.21; Pla: 1.09660.15 Abbreviations: Br – brain; He
– heart; Lu – lungs; Li – liver; Pa – pancreas; To – tongue; Hi – hindlimbs; BAT – Brown adipose tissue; Kid – kidneys; Pla – placenta. B. DLK1 protein
levels in transgenic and wild-type tissues. Western blot analysis of DLK1 protein levels in E18 70B transgenic and WT/WT liver, muscle and kidney
(negative control) and E16 placenta. For placenta, values normalised against tubulin are as follows: WT/WT= 1.0060.017; WT/TG= 1.18360.051 and
TG/TG= 1.533*60.073 (*for TG/TG p= 0.0417; paired non-parametric Freidman test). Antibodies used were anti-DLK1(DLK1) and anti a-TUBULIN (TUB)
as a normalization control.
doi:10.1371/journal.pgen.1000392.g002
Function of Dlk1 Dosage Control by Imprinting
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Figure 3. Transgenic expression in embryos recapitulates endogenous expression. A. WT/WT (left and middle) and TG/TG (right) e16 70B
embryos were sectioned, then in-situ hybridisation was performed using sense control (left panel) and antisense probes to Dlk1 (exons 3 to 5, middle
and right panels). No ectopic expression was observed. 2.56magnification. B. High power images of WT/WT (left) and TG/TG (right) kidney (206, top),
neck (106) and lung (406). In the WT/WT kidney, Dlk1 is largely absent except in the capsule and some punctuate staining in the mesenchyme. This
pattern is recapitulated in the TG/TG, with greater intensity. In the neck, Dlk1 is expressed in the ossifying cartilage of the spinal cord, in the muscle
and in the brown adipose tissue deposits, in both the WT/WT and TG/TG. In WT/WT lung Dlk1 is expressed in the epithelium of branching alveoli and
in the mesenchyme. This pattern is also clearly present in the TG/TG.
doi:10.1371/journal.pgen.1000392.g003
Function of Dlk1 Dosage Control by Imprinting
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gestation are due to oedema (Figure 6A–B). This late gestation
data correlates with lethality of the TG/TG fetuses commencing
around E16 (Table 1, Figure 4 and see below).
To determine the contribution of individual tissues to the
increase in fetal mass, E18–19 brains, livers, lungs, forelimbs,
hindlimbs and brown adipose tissue (BAT) were weighed and
analysed histologically (Figure 4C, Figure 5, Figure 6). In the
growth-enhanced WT/TG fetuses, lungs, forelimbs and hindlimbs
were proportionally heavier. WT/TG brains, that significantly
over-express Dlk1, were spared. E18 liver growth was unaffected,
suggesting that the milder Dlk1 over-expression in this tissue (E18:
1.31660.21 of WT/WT Dlk1 liver expression and at E16:
1.67660.21) may not be sufficient to cause overgrowth.
Overgrowth was observed in TG/TG livers evident from E16.
Histological examination revealed no obvious defects and portal
triads, and hepatocyte size appeared unaffected (Figure 4C,
Figure 6 and data not shown). In general, this suggests that, with
the exception of the brain, multi-organ overgrowth is associated
with Dlk1 over-expression in an organ-autonomous manner.
In the placentas, no significant differences between the
genotypes were observed at any stage (Figure 4A and Table S3).
Histological analyses indicated no obvious phenotypic abnormal-
ities in the placenta at E16 and E19 for the three genotypes (data
not shown). This is consistent with the finding that Dlk1 is
expressed at very low levels from the transgene in this tissue
(Figure 2 and Table S1) and suggests that embryonic growth
enhancement occurs independently of the placenta.
Dlk1 Dosage Modulates Skeletal Maturation
PatDi(12)/PatDp(dist12) and DIG-DMRMAT exhibit costal
cartilage defects and hypo-ossification of mesoderm-derived bones
[16,18,19]. Since WT/TG embryos have increased crown-rump
length, we examined the skeletal development of WT/TG and
TG/TG mice. WT/TG skeletons show signs of growth enhance-
Figure 4. Dlk1 over-expression causes tissue-specific growth enhancement. (A) Embryonic and placental growth of wild-type and
transgenic conceptuses and (B) embryonic dry masses and crown-rump lengths were measured from fetuses derived from heterozygous intercrosses
(n$5 litters; n$9 animals per genotype). Graphs represent mean values for each genotype within a litter6SEM for multiple litters. Significant
differences from wild-type are indicated by asterisks (p-value,0.05, paired, nonparametric Wilcoxon’s test). (C) Wet mass of E18 brain (Br), lungs (Lu),
liver (Li), forelimbs (Fo) and hindlimbs (Hi) and E19 brown adipose tissue (BAT) were measured in WT/WT, WT/TG and TG/TG fetuses (n$3 litters;
n$10 animals per genotype, except TG/TG forelimbs and hindlimbs where n = 4). Graph represents mean weight6SEM per genotype. Significant
differences from wild-type are indicated by asterisks on top of the WT/TG or TG/TG bar (p-value,0.05, unpaired Student’s t test). Data shown in this
figure are combined results from 70A, 70B and 70C.
doi:10.1371/journal.pgen.1000392.g004
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ment and minor ossification delays in the sternum and the closure
of the sagittal suture (Figure 5). Further increasing the dosage of
Dlk1 in TG/TG animals led to more severe skeletal defects.
Overall the TG/TG skeleton was smaller and the delay in the
closure of the sagittal suture was more pronounced. In addition,
we observed a bell-shaped thorax with a hypo-ossified sternum
and thinner ribs and vertebrae. We can therefore relate the
severity of hypo-ossification with increasing levels of Dlk1.
Another major defect associated with PatDi(12)/PatDp(dist12)
and DIG-DMRMAT is skeletal muscle immaturity [16,18,19].
Interestingly, in contrast to the defects in the skeleton, no muscle
maturation abnormalities were observed even when Dlk1 dosage
was tripled. Detailed morphometric analysis assessing myofiber
diameter and % of myofibers with centrally located nuclei was
performed on the E18 diaphragm and on a subset of muscles in
the forearm and no differences were observed (Figure S3). Dlk1
over-expression of all isoforms was confirmed at the protein level
(Figure 2B). Therefore our data clearly show no prenatal muscle
immaturity or hypertrophy induced by Dlk1 over-expression from
endogenous regulators.
Increasing Dlk1 Expression Reduces Embryonic and
Perinatal Fitness in a Dose-Dependent Manner
Hemizygous transgenic embryos are viable and fertile and
observed at Mendelian frequencies at birth indicating that a
double dose of Dlk1 expression is compatible with embryonic
viability (Table 1 and. Table S2). In contrast to WT/TG animals,
TG/TG embryos have distinct morphological features from E16
including severe oedema, a small thoracic region and a protruding
abdomen (Figure 6A and B). This is associated with lethality from
E16 with none of the TG/TG animals surviving more than a few
hours after birth (Table 1 and Table S2). We also observed that
the weight of the TG/TG lungs was significantly reduced
(Figure 4C) with a denser cellular arrangement at E18
(Figure 6C). Dlk1 is strongly expressed in the bronchioles of the
lung (Figure 3 and ref [10]) and an intrinsic defect in lung
development caused by over-expression of Dlk1 is likely to
contribute to the lethality of these animals.
Despite the absence of major embryonic abnormalities caused
by doubling Dlk1 dosage in vivo, we observed a significant increase
in early postnatal lethality in WT/TG animals. 32% of WT/TG
pups died during the first three days after birth compared to 10%
of WT/WT littermates, in crosses from wild type mothers (Table 1
and Table S2). In order to understand the cause of death, we
studied processes essential to early postnatal survival in rodents
such as temperature regulation, suckling ability and glucose
homeostasis.
Temperature regulation is required for adapting to cold
exposure after birth and relies on the process of non-shivering
thermogenesis (NST) mediated by brown adipose tissue (BAT)
metabolism. Dlk1 is believed to inhibit adipogenesis of both brown
and white adipose tissue [21,22] thus is a likely candidate for
involvement in the NST process. We measured BAT per body
weight and analysed markers for both fat differentiation (such as
Pparc2) and thermogenesis (such as Ucp1) before and after birth. At
E19, WT/TG BAT per body weight and levels of Pparc2 and Ucp1
are comparable to WT/WT (Figure S4). At birth, we observed
that Ucp1 and Pparc2 expression was slightly elevated, perhaps to
compensate for a slight decrease in BAT mass per body weight
(Figure 7A and B). Failure to thrive, therefore, cannot be ascribed
to compromised NST.
The suckling ability of Dlk1 WT/TG pups at birth was assessed
by using stomach weight as a measure of milk content [23]. We
observed that WT/WT animals were frequently found with
stomach content in the range of 0.03–0.08 grams, whilst WT/TG
animals never exceeded 0.03 grams (Figure 7A). In situ data shows
that at late gestation (E18), highest expression of Dlk1 is in the
tongue and the upper and lower lips, which is consistent with a
role of Dlk1 in suckling (Table S4 and data not shown). Blood
glucose levels were not different at birth between the two
genotypes (Figure 7C).
We also decided to monitor the growth performance of WT/
TG animals during the first three weeks of life, when juveniles are
still dependent on the mother for nutrition. WT/TG animals are
born bigger than their littermates (Figure 4A and Figure 7A), but
they fail to gain weight at the same rate as WT/WT neonates
during the first two weeks (Figure 7D). By 14 days, WT/TG
animals are small and remain small thereafter (,10%) (Figure 7D
and data not shown). The differences in growth performance are
most pronounced within the first week after birth (Figure 7D),
correlating with poor suckling and the increased lethality of these
animals. In conclusion, despite an early growth advantage, animals
expressing a double dose of Dlk1 fail to thrive in early life, and thus
any benefit conferred by an increased embryonic size is offset by
postnatal lethality.
Discussion
We have developed a unique model in which the consequences
of a single, double and triple dosage of one imprinted gene, Dlk1,
can be assessed in the growing embryo. The double dose is
reminiscent of the situation where there is no imprinting of this
gene. BAC and YAC transgenes have been widely used in mouse
genetics and in imprinting studies as a molecular tool for the
localisation of transcriptional or imprinting regulatory elements
[24,25,26]. We generated transgenes differing in the extent of the
sequences upstream of Dlk1. The TgDlk1-31 did not express Dlk1 in
four transgenic lines, regardless of integration site or copy number
(Figure S1A). In contrast, TgDlk1-70, which extends from 49 kb
upstream of the Dlk1 gene, is expressed. We have therefore
determined that the majority of embryonic tissue-specific enhancer
sequences for Dlk1 expression are located in the 8 kb to 49 kb
interval upstream of the gene. This is consistent with a previous
report showing that enhancers for Dlk1 are absent from 3 kb
upstream to 175 kb downstream of the gene [26]. Minimal
transgene expression in the placenta suggests the absence of the
specific regulatory sequences for this organ in the 70 kb transgene.
Table 1. Frequency and viability of Dlk1 transgenic mice from
E16 to early postnatal life.
TRANSMISSION GENOTYPE E16 E18–E19 P1–P3
Maternal WT/WT 37 29 -
TG/WT 48 47 (1) -
Paternal WT/WT 31 56 116 (12)
WT/TG 45 41 133 (42)*
Heterozygous Intercross WT/WT 34 58 13 (1)
WT/TG 87 (1) 153 23 (4)
TG/TG 37 (4) 80 (7) 7 (7)
The values represent number of animals genotyped in each time-point from
crosses involving Dlk1 transgenic animals; the numbers in brackets represent
number of dead animals.
*WT/TG neonatal lethality is statistically significantly increased compared to WT/
WT (p-value,0.01; X2-test).
doi:10.1371/journal.pgen.1000392.t001
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Figure 5. Skeletal defects in E19 WT/TG and TG/TG fetuses. A, Sagittal view of the whole skeleton. B, Frontal view of the thoracic cage. C,
Dorsal view of the vertebrae in the dorsal zone and D, cranial view of the skull of E19 WT/WT, WT/TG and TG/TG skeletons stained with Alcian Blue/
Alizarin Red. Arrow in B indicates the fifth ossification centre in the WT/WT sternum, absent in the WT/TG and TG/TG skeleton. Asterisk in D marks the
closure of the sagittal suture. Scale bars: 0.5 mm (B and C) and 1 mm (D). All images shown A–D are derived from 70A animals; results are exactly the
same for 70B and 70C.
doi:10.1371/journal.pgen.1000392.g005
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At E16, we detected growth enhancement in a Dlk1 dose-
dependent manner. TG/TG were more than 20% larger than
WT/WT littermates, whereas WT/TG were growth-enhanced by
10%. At later stages, progressive morbidity and mortality of TG/
TG embryos precluded a meaningful comparative assessment of
their growth rate. This was not the case for viable WT/TG
embryos which clearly maintained an increased growth trajectory
from E16 up to birth. This is reciprocal to the 20% reduction in
weight reported for Dlk1-null E19 fetuses [21]. In general, tissue-
specific overgrowth correlated with levels of Dlk1 over-expression,
except in the brain. This suggests Dlk1 acts locally on organ
growth, though we cannot rule out an endocrine role [27].
With the exception of studies on placental specific Igf2 [28,29],
previous functional analyses of imprinted genes expressed in
embryo and placenta have not been able to discern whether
growth effects are intrinsic to the embryo or are secondary to
placental function. This is because genetic manipulation of
imprinted genes often results in altered gene dosage in both
embryonic and extra-embryonic tissues [reviewed in 30]. In
contrast, the WT/TG model reported here generates embryonic
Dlk1 over-expression in the presence of a normal placenta with a
normal Dlk1 dose, and the results indicate that Dlk1 can modulate
embryonic growth independently of the placenta. To complement
these studies, it will be important to determine the extent to which
placental Dlk1 expressed in the fetal endothelium and some
trophoblast cells of the labyrinthine zone [10] also contributes to
embryonic growth.
Importantly, this study shows that Dlk1 has a dual role on
growth. WT/TG neonates are born larger but fail to thrive during
the first week of life. The reduced postnatal growth rate is
concurrent with reduced food intake in the neonatal period.
Maternally repressed imprinted genes are expected to favour
growth performance and resource acquisition from embryonic
stages to weaning according to the kinship theory which posits that
imprinting arose as a consequence of a conflict between males and
females over the allocation of maternal resources to the offspring
[31,32]. The embryonic overgrowth generated by Dlk1 double
dosage follows the directionality predicted by this theory however
the postnatal failure to thrive phenotype is contrary to it. Our
model implicates Dlk1 in reduced postnatal nutrient acquisition.
Indeed the results suggest that maternal repression of Dlk1 may
have evolved to increase postnatal nutrient acquisition. Further-
more it has been hypothesized that maternally repressed imprinted
genes, such as Dlk1, would minimize heating contribution within
huddles [33,34]. NST is not impaired in BAT over-expressing
Dlk1. In fact, slight over-expression of Pparc2 and Ucp1 may
suggest the opposite scenario, whereby a maternally repressed
gene may contribute more to the communal heating. Our results
are therefore inconsistent with the conflict hypothesis. It is possible
that imprinting may have evolved due to more than one type of
selective pressure, perhaps different for different domains.
In TG/TG embryos over-growth occurs at E16 coincident with
an increased frequency of embryonic mortality. Embryos express-
ing this triple dose did not survive past birth. A double dose of Dlk1
was compatible with embryonic viability but resulted in significant
neonatal lethality. We propose a negative correlation between
gene dosage and survival that may fix an upper limit on growth
promotion by Dlk1.
One hypothesis for the lethality could be that Dlk1 dosage
regulates the balance between proliferation and differentiation
resulting in a trade-off between pre-natal size and developmental
maturity. Increasing Dlk1 dosage incrementally shifts the embryo
towards increased growth, perhaps at the expense of organ
maturation as was suggested for PatDi(12) embryos [16]. The
major abnormalities found in the liver, lungs and skeleton of the
TG/TG fetuses may be signs of developmental immaturity of these
organs. The inability of the lungs to support TG/TG animals
surviving to term, as well as pre-natal oedema, is consistent with this.
The Notch signalling pathway is required for branching morpho-
genesis and maturation of the lungs, and disruption of this pathway
can lead to peri-natal lethality due to lung hypotrophy [reviewed in
35, 36, 37]. In contrast, except for subtle ossification delays in the
WT/TG fetuses, no other clear signs of organ immaturity were
identified, so we cannot conclude whether this contributes to the
neonatal lethality of the hemizygous genotype.
In order to explore the cause of lethality in the WT/TG
neonates more closely, we measured several parameters related to
rodent well-being. WT/TG animals were significantly less likely to
have milk-filled stomachs on the day of birth. This may be a result
of defects in suckling behaviour engendered by many causes, such
as appetite or olfactory regulation, or motor function. Starvation
may therefore be the cause of death of WT/TG neonates, and
reduced feeding in the first week is also a likely cause of the
reduced growth rate of surviving transgenic animals during this
period. Further analysis of the physiological consequences of this
interesting growth trajectory of prenatal growth enhancement
followed by postnatal compromised growth is in progress.
Figure 6. TG/TG fetuses exhibit major developmental abnor-
malities. A. E19 WT/WT WT/TG and TG/TG fetuses. B. Comparable mid-
sagittal H&E sections through E18 WT/WT, WT/TG, and TG/TG fetuses. C.
H&E stained sections through E18 lungs showing dense cellular
arrangement in TG/TG lung. Sections shown are from 70A animals;
results are the same for 70B and 70C. N63 samples from each genotype
were analysed for each line. Scale bar in A and B: 1 mm; Scale bar in C:
100 mm.
doi:10.1371/journal.pgen.1000392.g006
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Figure 7. Poor early post-natal fitness in animals with Dlk1 double dose. A. Neonatal total mass (left panel) and organ weights (right panels)
at birth (P1). Graphs represent weight of individual animals/organs. Significant differences from wild-type are indicated by asterisks on top of the WT/
TG (p-value,0.05, unpaired Student’s t test). For stomach weights, the non-parametric Mann-Whitney U-test was performed (p-value,0.05). B. BAT
expression analysis by TaqMan RT-qPCR. Graphic representation of relative levels of expression of Dlk1, Pparc2 and Ucp1 normalized against 18S
(loading control) at P1 (mean6SEM, n$4). Significant differences between WT/TG and WT/WT for each gene are indicated by asterisks on top of the
WT/TG bar (p-value,0.05; unpaired Student’s t test). C. Free-fed glycemia at P1; Graph represents individual levels of glycemia (n$15). D. The left
panel represents the pre-weaning growth curve of WT/WT and WT/TG male juveniles. Graph represents mean values6SEM per genotype (n$7).
Significant reduced weight from WT/WT is indicated by # and significant increased weight from WT/WT is indicated by * (p-value,0.05, unpaired
Student’s t test). The right panel shows the growth rate of WT/WT and WT/TG animals in the first 5 weeks of age (calculated using the following
formula: for week n: [weight at week n – weight at week (n-1)]/weight at week n. All data shown in A–D are the combined results for the three
transgenic lines.
doi:10.1371/journal.pgen.1000392.g007
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Imprinting of the Dlk1-Dio3 cluster is important. Disruption of
imprinted expression in several models results in lethality therefore
there is a clear selective pressure to maintain imprinting at this
cluster [13,38]. The IG-DMR, like other imprinting control
regions, controls the dosage of many linked genes. It has been
postulated that in imprinted clusters, some genes are the target of
dosage regulation while other are merely bystanders whose altered
dosage do not have phenotypic consequences and therefore are
not targets for selection [39]. We show that Dlk1 is a dose-
dependent regulator of embryonic growth, as well as modulating
processes necessary for postnatal survival. WT/TG animals model
loss of imprinting of Dlk1, and have significantly reduced fitness,
suggesting that the maintenance of imprinting of solely Dlk1 in
eutherians by the IG-DMR has been sufficient to selectively retain
imprinting control of the entire chromosome 12 cluster. However,
the phenotypes of PatDi(12)/PatDp(dist12) and DIG-DMRMAT
embryos are much more severe than that of a Dlk1 double-dose
alone; therefore the dosage of at least one other gene in this cluster
requires tight regulation. Rtl1 is a likely candidate for this as defects
have been reported in both knockout and overexpression models
[38] and this gene is found only in eutherian mammals that have
imprinting [12].
We cannot know the selective pressures surrounding the
acquisition of imprinting at chromosome 12 in eutherians however
this mechanism must have evolved to regulate dosage-critical
genes. We have shown Dlk1 to be such a dosage-critical gene
through its significant consequences on animal fitness upon dosage
modulation. It therefore could have been the target of selection for
dosage control by imprinting at this locus. Current levels of Dlk1
represent an optimal balance of maximized growth with minimal
neonatal lethality.
Materials and Methods
Generation and Breeding of Transgenic Animals
TgDlk1-31 and TgDlk1-70 transgenes were obtained by restriction
endonuclease mapping of the BAC clone 163O05, screened from
a BAC library of the mouse strain 129/Sv. The two transgenes
were microinjected individually into the male pronuclei of
(C57BL/66CBA) F1 zygotes and then implanted into foster
(C57BL/66CBA) F1 mothers. The first generation of animals was
obtained by crossing the founder with a (C57BL/66CBA) F1
animal. After the first generation, all transgenic animals were
mated on a C57BL/6 background to maintain the lines. Animals
were housed four per cage (maximum) in a temperature-controlled
room (24uC) with a 12-hr light/dark cycle. Food and water were
available ad libitum. All experiments involving mice were carried
out in accordance with UK Government Home Office licensing
procedures. For the embryonic studies, the day of vaginal plug was
considered day E1.
Expression Studies
RNA was extracted from whole embryos using TRI Reagent
(Ambion), following the manufacturer’s guidelines. mRNA was
then isolated from 120 mg of total RNA using Dynalbeads Oligo
(dT)25 kit (Dynal) following the supplied protocol. We carried out
northern-blot hybridization and used probes as described
previously for Dlk1 and Gtl2 and Gapdh [3]. For RT-qPCR, total
RNA (10 mg) was DNase-treated with RQ1 RNase-free DNase
(Promega) following the manufacturer’s guidelines. All cDNA was
synthesized using random hexamers and Superscript III RNase
H2 Reverse Transcriptase (Invitrogen), following standard
procedures.
Taqman quantitative real-time PCR (qRT-PCR) was used to
measure expression levels of Dlk1 and Gtl2 normalized to b-2-
microglobulin (b2m) in different E16 and E18 embryonic tissues. All
RT-qPCR reactions were performed in a 25 ml final volume using
standard Taqman qPCR conditions (Appplied Biosystems proto-
cols) and amplified on a DNA engine Opticon 2 thermocycler (MJ
Research). All reactions were conducted in triplicate. Dlk1
expression levels were measured using the TaqMan gene
expression assay ID - Mm00494477_m1 (Applied Biosystems).
Gtl2 gene expression was measured using the forward primer 59-
GGGCGCCCACAGAAGAA-39, the reverse primer 59-
GGTGTGAGCCGATGATGTCA-39 and the TaqMan MGB
FAM probe FAM-59-CTCTTACCTGGCTCTCT-39-NFQ,
spanning the Gtl2 exon 1-exon 2 boundary. Finally, for the b2m
gene, the forward primer B2M-32 59-CACCCCCACTGAGACT-
GATACA-39, the reverse primer B2M-38 59-
TGGGCTCGGCCATACTG-39 and the TaqMan MGB VIC-
labelled fluorogenic probe VIC-59-CCTGCAGAGTTAAGC-39-
NFQ were used. Relative expression was calculated by normal-
isation to 100% using fetal E18 WT/WT tongue for the
expression profile of the embryonic tissues and quantified using
the comparative method (22dCt) [40]. Pparc2 and Ucp1 analysis
was performed as previously described [41]. The fluorescent signal
emitted during PCR was detected using the DNA engine Opticon
2 sequence detection system (MJ Research) and post-PCR data
analysis was performed using the Opticon Monitor analysis
software version 2.02 (MJ Research).
In situ hybridisation was conducted on paraformaldehyde fixed,
wax embedded embryo and placenta sections at E16 and E18 of
gestation according to the procedures previously described [42].
DLK1 Protein Analysis
Tissue lysates from whole embryos, whole placentas and
multiple organs were used for SDS/PAGE analysis with a 10%
polyacrylamide gel. Resolved proteins were transferred to a poly-
vinylidene difluoride (PVDF) Western blotting membranes
Immobilon-P (Millipore) which were incubated with anti-DLK1
H-118 rabbit polyclonal antibody (1:500) (Santa Cruz Biotech-
nology) or anti-DLK1 (1:500) for placenta (Proteintech) and anti-
a-TUBULIN mouse monoclonal antibody (Sigma) (1:5000)
overnight at 4uC, followed by the secondary HRP-conjugated
antibodies: polyclonal goat anti-rabbit (1:5000) or polyclonal goat
anti-mouse (1:7500) (DakoCytomotion), respectively, on the next
day. Any signal was detected using ECL plus Western Detection
System (Amersham Biosciences). The intensity of the signal was
measured by scanning densiometry using Image J software (NIH).
Phenotypic Characterisation of Dlk1 Transgenic Fetuses
and Neonates
All embryonic dissections were recorded in terms of number
and genotype of embryos/pups, dead embryos/pups, necrotic
embryos and reabsorptions for all Dlk1 transgenic families. Wet
masses were recorded for all fetuses/newborns/juveniles and
placentas dissected at different developmental stages. Wet organ
weights were also determined for E18, E19 and P1. For
determination of the dry weight, pre-weighed embryos were dried
by incubation at 60uC for 48 h plus 100uC for a further 24 h and,
then, weighed. Crown-Rump length was accurately measured
using callipers. Glycemia levels were measured using a One Touch
Ultra glucometer (Lifescan).
For histology, freshly harvested embryos were fixed in 4%
paraformaldehyde overnight at 4uC, dehydrated and embedded in
paraffin wax using standard protocols. Sections of 7–10 mm were
cut and 1 section in 10 was stained with Haematoxylin and Eosin
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(H&E). For skeletal preparation, the skeleton of E19 embryos was
stained with Alcian Blue and Alizarin Red as described previously
[16]. Muscle was analysed after immunocytochemistry with MY32
antibody (M4276 Sigma), a monoclonal antibody specific for
skeletal muscle myosin heavy chain, performed according to the
procedure described previously [16]. Comparative morphometrics
were carried out on MY32-stained histological sections through
the largest cross-sectional area of the forelimbs and diaphragm.
Comparable sections were carefully selected for the TG/TG,
WT/TG and WT/WT littermates and 3 sections (7 mm thick)
with 20 section intervals were selected for each embryo.
Measurements were performed by randomly selecting the fields
across the whole section. Details were as described previously [19].
Ethics statement
All animal work in this study was conducted under a licence
(80/2042) from the UK Government Home Office.
Supporting Information
Figure S1 Dlk1 transgene copy number and expression. A.
Schematic representation of the endogenous and transgenic Dlk1
locus; Restriction digestion with EcoRI (arrows) results in a 4.5 kb
band for the endogenous gene and a 4.0 kb band for the
transgenic copy, when detected by the probe represented in green.
B. Determination of copy number in transgenic and normal (N)
animals from different families (upper panel). Genotyping of the
WT/TG and TG/TG animals of the 70C and 70A families (lower
panels).
Found at: doi:10.1371/journal.pgen.1000392.s001 (2.47 MB TIF)
Figure S2 TgDlk1-70 is expressed at at double dose in all three
lines and is not imprinted. A. Sequence analysis of RT–PCR
products from E16 WT/WT, TG/WT (maternal transmission)
and WT/TG (paternal transmission) embryos showing expression
of the transgene regardless of parental-origin; the endogenous
locus is indicated by the T allele (DBA/2) in the nucleotide marked
by the arrow head, while the transgene is indicated by the C allele
(129/Sv). Allele-specific sequence analysis was conducted for 70B
and 70C families. B. Quantitative Northern blotting and
histograms showing that Dlk1 is expressed at twice the normal
dose in WT/TG animals in all three transgenic lines analysed.
Found at: doi:10.1371/journal.pgen.1000392.s002 (3.57 MB TIF)
Figure S3 Transgenic mice do not have skeletal muscle defects.
A. Comparable sections through the diaphragm of E18 PatDi(12),
WT/WT, WT/TG and TG/TG fetuses stained with the myofibril
specific antibody MY32. Scale bar: 50 mm. B. Morphometric
analysis of the skeletal muscle of E18 WT/WT, WT/TG and
TG/TG fetuses (a) Standard section through the forearm stained
with MY32 antibody; Forel I (extensor carpi radialis long-
us+brachioradialis), Forel II (extensor digitorum+extensor carpi
ulnaris) were used for morphometric measurements; Scale bar:
200 mm; Abbreviations: r -radius; u -ulna. (b) Morphometric
analysis of the myofiber diameter of the skeletal muscles
(diaphragm, forel I and forel II) of E18 WT/WT, WT/TG and
TG/TG. Graphs show mean values6SEM (n$4). (c) Morpho-
metric analysis of the percentage of myofibers with centrally-
located nuclei from the same material used to analyse myofiber
diameter; Graphs show mean values6SEM (n$4).
Found at: doi:10.1371/journal.pgen.1000392.s003 (2.32 MB TIF)
Figure S4 BAT expression analysis by TaqMan RT-qPCR at
E19. Graphic representation of relative levels of expression of
Pparc2 and Ucp1 normalized against 18S (loading control) at E19
(mean6SEM, n$6) (70B).
Found at: doi:10.1371/journal.pgen.1000392.s004 (0.43 MB TIF)
Table S1 Summary of the copy number and Dlk1 expression
levels in E16 WT/TG fetuses relative to wild type for the 70 kb
Dlk1 transgenic lines. Significant differences in expression for the
different families are indicated by asterisks (p-value,0.05;
unpaired student’s t-test); Abbreviations: F3 - Generation 3.
Found at: doi:10.1371/journal.pgen.1000392.s005 (0.05 MB
DOC)
Table S2 Frequency and viability of WT/WT, WT/TG and
TG/TG animals from E16 to early postnatal life for the three
over-expressing 70 kb transgenic lines (70A, 70B and 70C). The
values represent number of animals genotyped in each time-point
from crosses involving Dlk1 transgenic animals; the numbers in
brackets represent number of dead animals.
Found at: doi:10.1371/journal.pgen.1000392.s006 (0.06 MB
DOC)
Table S3 Overall embryonic and placental growth of Dlk1
transgenic fetuses from the three over-expressing 70 kb transgenic
lines (70B, 70A and 70C). Values represent mean6SEM; Means
were obtained from fetuses originated from at least three
independent heterozygous intercross litters (n$5). Percentage
values represent the ratio between WT/TG or TG/TG weights to
the WT/WT counterparts. Significant differences between the
WT/TG and WT/WT and between TG/TG and WT/WT are
indicated by asterisks on the percentage value (unpaired Student’s
t test).
Found at: doi:10.1371/journal.pgen.1000392.s007 (0.07 MB
DOC)
Table S4 Comparison of expression of Dlk1 between WT/WT
and WT/TG or TG/TG embryos. In situ hybridisation was
conducted on E16 and E18 conceptuses using antisense and sense
(control) probes for Dlk1. Sections were scored for expression of
Dlk1. Expression of Dlk1 was evident in all endogenous sites and
ectopic expression was not observed in transgenic embryos or
placentas.
Found at: doi:10.1371/journal.pgen.1000392.s008 (0.04 MB
DOC)
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